Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP5K1C | O60331 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | ITK | Q08881 | 3/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | INSR | P06213 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479952 | 0.71 | ITK (0.57) | PIP5K1CITKCNR2 | |
| SCHEMBL2735969 | 0.68 | CA12 (0.72) | IDO1 | |
| SCHEMBL5755119 | 0.68 | HSP90AA1 (0.57) | PIP5K1CITKINSRCCNE1CDK2 | |
| SCHEMBL17680257 | 0.68 | COMT (0.49) | IDO1ITKMAPT | |
| SCHEMBL1853621 | 0.65 | ALDH1A1 (0.48) | IDO1 | |
| SCHEMBL34468710 | 0.65 | KDM4E (0.64) | CNR2 | |
| SCHEMBL3992778 | 0.64 | IDO1 (0.56) | IDO1MAPT | |
| SCHEMBL24471488 | 0.63 | IDO1 (0.54) | IDO1MAPT | |
| SCHEMBL27427552 | 0.63 | CA12 (0.56) | IDO1 | |
| SCHEMBL1260046 | 0.62 | ASAH1 (0.48) | ASAH1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032869-A1 | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032869-A1 | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K9, MAP3K20, MAP3K19 | PIP5K1C 70/4885IDO1 234/4885ITK 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.